CN1871347B - 引起硬化的增殖性疾病的检测方法和试剂盒、引起硬化的增殖性疾病的预防和/或治疗药、以及对在引起硬化的增殖性疾病的预防和/或治疗中有效的物质进行鉴定的方法和试剂盒 - Google Patents
引起硬化的增殖性疾病的检测方法和试剂盒、引起硬化的增殖性疾病的预防和/或治疗药、以及对在引起硬化的增殖性疾病的预防和/或治疗中有效的物质进行鉴定的方法和试剂盒 Download PDFInfo
- Publication number
- CN1871347B CN1871347B CN2004800263069A CN200480026306A CN1871347B CN 1871347 B CN1871347 B CN 1871347B CN 2004800263069 A CN2004800263069 A CN 2004800263069A CN 200480026306 A CN200480026306 A CN 200480026306A CN 1871347 B CN1871347 B CN 1871347B
- Authority
- CN
- China
- Prior art keywords
- smad1
- expression
- psmad1
- activin acceptor
- sample kinases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003319538 | 2003-09-11 | ||
JP319538/2003 | 2003-09-11 | ||
PCT/JP2004/013124 WO2005026344A1 (ja) | 2003-09-11 | 2004-09-09 | 硬化をもたらす増殖性疾患の検出方法及びキット、硬化をもたらす増殖性疾患の予防及び/又は治療剤、ならびに硬化をもたらす増殖性疾患の予防及び/又は治療に有効な物質を同定する方法及びキット |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1871347A CN1871347A (zh) | 2006-11-29 |
CN1871347B true CN1871347B (zh) | 2011-05-25 |
Family
ID=34308570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800263069A Active CN1871347B (zh) | 2003-09-11 | 2004-09-09 | 引起硬化的增殖性疾病的检测方法和试剂盒、引起硬化的增殖性疾病的预防和/或治疗药、以及对在引起硬化的增殖性疾病的预防和/或治疗中有效的物质进行鉴定的方法和试剂盒 |
Country Status (8)
Country | Link |
---|---|
US (3) | US7901874B2 (zh) |
EP (2) | EP1672062B1 (zh) |
JP (2) | JP4664815B2 (zh) |
KR (1) | KR101242260B1 (zh) |
CN (1) | CN1871347B (zh) |
AT (1) | ATE557087T1 (zh) |
HK (1) | HK1097880A1 (zh) |
WO (1) | WO2005026344A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE557087T1 (de) * | 2003-09-11 | 2012-05-15 | Hubit Genomix Inc | Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz |
EP2574625B1 (en) | 2006-07-21 | 2015-02-25 | HuBit genomix, Inc. | Remedy for renal disease |
KR20090035581A (ko) * | 2006-08-04 | 2009-04-09 | 아지노모토 가부시키가이샤 | 신장 기능 장해 예방ㆍ치료제 |
CN104997774A (zh) | 2009-04-10 | 2015-10-28 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
US20130078660A1 (en) * | 2010-03-23 | 2013-03-28 | Salk Institute For Biological Studies | Methods and compositions for detecting protein modifications |
JP5346360B2 (ja) * | 2010-08-31 | 2013-11-20 | 株式会社マルハニチロ食品 | 塩分の吸収阻害作用をもつ血管保護剤 |
WO2012170037A1 (en) | 2011-06-10 | 2012-12-13 | Hitachi Chemical Co., Ltd. | Vesicle capturing devices and methods for using same |
WO2014055687A1 (en) | 2012-10-05 | 2014-04-10 | Hitachi Chemical Co., Ltd. | Urine exosome mrnas and methods of using same to detect diabetic nephropathy |
WO2014182330A1 (en) | 2013-05-06 | 2014-11-13 | Hitachi Chemical Company Ltd | Devices and methods for capturing target molecules |
US10266895B2 (en) | 2014-11-05 | 2019-04-23 | Hitachi Chemical Company Ltd. | Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease |
WO2016077537A1 (en) | 2014-11-12 | 2016-05-19 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
JP2017538698A (ja) * | 2014-12-03 | 2017-12-28 | ウェイン ステート ユニバーシティー | 増殖性障害に関連する組成物及び方法 |
JP6329501B2 (ja) * | 2015-03-11 | 2018-05-23 | アース環境サービス株式会社 | 昆虫の混入時期判定方法 |
CN106338423B (zh) | 2015-07-10 | 2020-07-14 | 三斯坎公司 | 组织学染色的空间复用 |
DE112016003948T5 (de) | 2015-08-31 | 2018-05-09 | City Of Sapporo | Molekulare verfahren zum beurteilen einer urothelialen erkrankung |
AU2017338353B2 (en) * | 2016-10-03 | 2024-04-04 | Fuso Pharmaceutical Industries,Ltd. | Inspection method enabling specific diagnosis of pathological state of diabetic nephropathy at early stage |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1409722A (zh) * | 1999-06-11 | 2003-04-09 | 纽约州州立大学研究基金会 | BMP和TGFβ信号转导途径的拮抗剂 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
AU6592896A (en) * | 1995-07-21 | 1997-02-18 | Regents Of The University Of Minnesota | Analysis of alpha integrins for the diagnosis of diabetic nephropathy |
US5908925A (en) * | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
EP1146869A2 (en) * | 1999-01-27 | 2001-10-24 | University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
AU2001251612A1 (en) * | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
JP4267864B2 (ja) | 2002-04-18 | 2009-05-27 | 古河電気工業株式会社 | フラットワイヤハーネスの長さ調節治具 |
AU2003268219B2 (en) * | 2002-08-28 | 2009-09-24 | Barnes-Jewish Hospital | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
WO2005002416A2 (en) * | 2003-06-04 | 2005-01-13 | Joslin Diabetes Center, Inc. | Predictors of renal disease |
ATE557087T1 (de) * | 2003-09-11 | 2012-05-15 | Hubit Genomix Inc | Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz |
EP2574625B1 (en) * | 2006-07-21 | 2015-02-25 | HuBit genomix, Inc. | Remedy for renal disease |
US8926710B2 (en) * | 2010-10-25 | 2015-01-06 | Warsaw Orthopedic, Inc. | Osteoinductive bone graft injectable cement |
-
2004
- 2004-09-09 AT AT04787788T patent/ATE557087T1/de active
- 2004-09-09 EP EP04787788A patent/EP1672062B1/en active Active
- 2004-09-09 JP JP2005513889A patent/JP4664815B2/ja active Active
- 2004-09-09 EP EP10010148A patent/EP2261331A1/en not_active Withdrawn
- 2004-09-09 US US10/571,511 patent/US7901874B2/en active Active
- 2004-09-09 KR KR1020067004858A patent/KR101242260B1/ko active IP Right Grant
- 2004-09-09 CN CN2004800263069A patent/CN1871347B/zh active Active
- 2004-09-09 WO PCT/JP2004/013124 patent/WO2005026344A1/ja active Application Filing
-
2007
- 2007-05-21 HK HK07105351.5A patent/HK1097880A1/xx unknown
-
2009
- 2009-09-28 US US12/585,882 patent/US9359645B2/en not_active Expired - Fee Related
-
2010
- 2010-09-29 JP JP2010218011A patent/JP5199322B2/ja active Active
-
2016
- 2016-05-04 US US15/146,515 patent/US20160333412A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1409722A (zh) * | 1999-06-11 | 2003-04-09 | 纽约州州立大学研究基金会 | BMP和TGFβ信号转导途径的拮抗剂 |
Non-Patent Citations (4)
Title |
---|
AKIO HORIGUCHI, ET AL,.ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOROF TRANSCRIPTION 3 IN RENAL CELL CARCINOMA: ASTUDY OF INCIDENCE AND ITS ASSOCIATION WITHPATHOLOGICAL FEATURES AND CLINICAL OUTCOME.THE JOURNAL OF UROLOGY168 2.2002,168(2),第762页"摘要"中的"结论",第763页"材料与方法"中的"免疫组化"段落. |
AKIO HORIGUCHI, ET AL,.ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOROF TRANSCRIPTION 3 IN RENAL CELL CARCINOMA: ASTUDY OF INCIDENCE AND ITS ASSOCIATION WITHPATHOLOGICAL FEATURES AND CLINICAL OUTCOME.THE JOURNAL OF UROLOGY168 2.2002,168(2),第762页"摘要"中的"结论",第763页"材料与方法"中的"免疫组化"段落. * |
XIAODAN WANG, ET AL,.INHIBITION OF THE JAK/STAT SIGNALINGPATHWAYPREVENTS THE HIGH GLUCOSE-INDUCEDINCREASE INTGF-β AND FIBRONECTIN SYNTHESIS INMESANGIALCELLS.DIABETES51 12.2002,51(12),第3505页实验设计与方法、材料,图2,第3509页第1段. |
XIAODAN WANG, ET AL,.INHIBITION OF THE JAK/STAT SIGNALINGPATHWAYPREVENTS THE HIGH GLUCOSE-INDUCEDINCREASE INTGF-β AND FIBRONECTIN SYNTHESIS INMESANGIALCELLS.DIABETES51 12.2002,51(12),第3505页实验设计与方法、材料,图2,第3509页第1段. * |
Also Published As
Publication number | Publication date |
---|---|
US9359645B2 (en) | 2016-06-07 |
KR20070026303A (ko) | 2007-03-08 |
EP1672062B1 (en) | 2012-05-09 |
US7901874B2 (en) | 2011-03-08 |
CN1871347A (zh) | 2006-11-29 |
EP2261331A1 (en) | 2010-12-15 |
WO2005026344A1 (ja) | 2005-03-24 |
JP5199322B2 (ja) | 2013-05-15 |
KR101242260B1 (ko) | 2013-03-13 |
EP1672062A1 (en) | 2006-06-21 |
ATE557087T1 (de) | 2012-05-15 |
US20160333412A1 (en) | 2016-11-17 |
US20100135988A1 (en) | 2010-06-03 |
JPWO2005026344A1 (ja) | 2007-11-08 |
EP1672062A4 (en) | 2007-10-31 |
JP2011050383A (ja) | 2011-03-17 |
US20080025967A1 (en) | 2008-01-31 |
JP4664815B2 (ja) | 2011-04-06 |
HK1097880A1 (en) | 2007-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5199322B2 (ja) | 硬化をもたらす増殖性疾患の検出方法及びキット、硬化をもたらす増殖性疾患の予防及び/又は治療剤、ならびに硬化をもたらす増殖性疾患の予防及び/又は治療に有効な物質を同定する方法及びキット | |
La Fortezza et al. | JAK/STAT signalling mediates cell survival in response to tissue stress | |
Mejlvang et al. | Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition | |
Spiegel et al. | Npas4 regulates excitatory-inhibitory balance within neural circuits through cell-type-specific gene programs | |
Baczyk et al. | Complex patterns of GCM1 mRNA and protein in villous and extravillous trophoblast cells of the human placenta | |
Lupia et al. | CD63 tetraspanin is a negative driver of epithelial-to-mesenchymal transition in human melanoma cells | |
Alexander et al. | Normal cells control the growth of neighboring transformed cells independent of gap junctional communication and SRC activity | |
Hsiao et al. | Gli2 modulates cell cycle re-entry through autophagy-mediated regulation of the length of primary cilia | |
OLSEN et al. | Converging signals synergistically activate the LAMC2 promoter and lead to accumulation of the laminin gamma2 chain in human colon carcinoma cells | |
Yada et al. | Microphysiological head and neck cancer model identifies novel role of lymphatically secreted monocyte migration inhibitory factor in cancer cell migration and metabolism | |
Widau et al. | p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms | |
Ueberham et al. | Smad2 isoforms are differentially expressed during mouse brain development and aging | |
Toyama et al. | Ninjurin1 increases p21 expression and induces cellular senescence in human hepatoma cells | |
US9574240B2 (en) | Gene amplification of coactivator CoAA and uses thereof | |
EP1739186B1 (en) | Method of screening compound capable of accelerating or inhibiting apoptosis, apoptosis accelerator and apoptosis inhibitor | |
Wu et al. | Crk and Crkl Are Required in the Endocardial Lineage for Heart Valve Development | |
Vidal et al. | Paracrine and autocrine R-spondin signalling is essential for the maintenance and differentiation of renal stem cells | |
US20210071257A1 (en) | Compositions and methods for maintaining splicing fidelity | |
WO2008094709A2 (en) | Methods and compositions for treating t-cell leukemia | |
Hao et al. | Somatic PDGFRB activating variants promote smooth muscle cell phenotype modulation in intracranial fusiform aneurysm | |
Martens | SUPPLEMENTARY MATERIALS AND METHODS | |
Zhang | Functional Analysis of a RAD21 Variant Identified from a Sclerocornea Pedigree | |
Hu et al. | 3’UTR-dependent dynamic changes in TP53 mRNA localization regulate p53 tumor suppressor activity | |
JP2020101461A (ja) | 老化抑制剤のスクリーニング方法 | |
Mueller | Characterizing the Role of the Previously Undescribed Protein Caskin2 in Vascular Biology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1097880 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1097880 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: DOI TOSHIO Free format text: FORMER OWNER: DOI TOSHIO CHUGAI SEIYAKU KABUSHIKI KAISHA Effective date: 20140728 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140728 Address after: Tokyo, Japan Patentee after: Hubit Genomix Inc. Patentee after: Doi Toshio Address before: Tokyo, Japan Patentee before: Hubit Genomix Inc. Patentee before: Doi Toshio Patentee before: Chugai Pharmaceutical Co., Ltd. |